EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Identifying differential predictors for treatment response to amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill patients with schizophrenia: Results of the COMBINE-study

Viktoria Galuba, Joachim Cordes, Sandra Feyerabend, Mathias Riesbeck, Eva Meisenzahl-Lechner, Christoph U Correll, Michael Kluge, Andrea Neff, Mathias Zink, Berthold Langguth, Dirk Reske, Gerhard Gründer und 7 weitere

Schizophrenia Research · 2024

DOI: 10.1016/j.schres.2024.06.033 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Schizophrenia Research, 2024. Verfasst von Viktoria Galuba und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Psychotherapy, Medical Center, University of Freiburg, Faculty of Medicine, University of Freiburg, Germany; LVR-Clinic …. Hauptthemen laut MEDLINE: Amisulpride, Olanzapine, Antipsychotic Agents, Schizophrenia. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Bundesministerium für Bildung und Forschung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Extensive research has been undertaken to predict treatment response (TR) to antipsychotics. Most studies address TR to antipsychotics in general and as monotherapy, however, it is unknown whether patients might respond favourably to a combination of antipsychotics. AIMS: This study aimed to identify differential predictors for TR to monotherapy with amisulpride or olanzapine compared to a combination of antipsychotics. METHODS: Post-hoc analysis was conducted of data collected from the COMBINE-study, a double-blind, randomized, controlled trial. Demographic and disease-related measures were gathered at baseline to predict TR after eight weeks defined by the Positive and Negative Syndrome Scale. Missing values were accounted for by a random replacement procedure. Attrition effects and multicollinearity were analysed and sets of logistic regression models were calculated for different treatment groups. RESULTS: Of the 321 randomized patients, 201 completed procedures until week eight and 197 were included in the analyses. For all treatment groups, early TR after two weeks and high subjective well-being under antipsychotics at baseline were robust predictors for TR. The propensity for early side effects also indicated a higher risk of later non-response. Specific parameter estimates were rather similar between treatment groups. CONCLUSION: Early TR, drug-related subjective well-being, and early side effect propensity evolved as predictors for later TR whether to monotherapy or combination strategy. Accordingly, due to a lack of differential predictors, early and close monitoring of targeted and unwanted effects is indicated to guide respective treatment decisions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AmisulprideOlanzapineAntipsychotic AgentsSchizophreniaDrug Therapy, CombinationHumansFemaleMaleAdultDouble-Blind MethodMiddle AgedTreatment OutcomeAcute DiseaseYoung AdultSulpiridePsychiatric Status Rating Scales

Stichwörter der Autor:innen

AntipsychoticCombinationPredictionResponseSchizophreniaTreatment

Substanzen

AmisulprideOlanzapineAntipsychotic AgentsSulpiride

Autor:innen und Institutionen

  • Department of Psychiatry and Psychotherapy, Medical Center, University of Freiburg, Faculty of Medicine, University of Freiburg, Germany; LVR-Clinic Düsseldorf, Department of Psychiatry and Psychotherapy, Faculty of Med…
  • LVR-Clinic Düsseldorf, Department of Psychiatry and Psychotherapy, Faculty of Medicine, Heinrich-Heine-University, Germany; Kaiserswerther Diakonie, Florence Nightingale Hospital, Department of Psychiatry and Psychother…
  • LVR-Clinic Düsseldorf, Department of Psychiatry and Psychotherapy, Faculty of Medicine, Heinrich-Heine-University, Germany.
  • Department of Psychiatry and Psychotherapy, Faculty of Medicine, Heinrich-Heine-University, LVR Düsseldorf, Germany.
  • Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA; The Zucker Hillside Hospital, Psychiatry Research, Northwell Health, Glen Oaks, NY,…
  • Department of Psychiatry and Psychotherapy, University Hospital Leipzig, Leipzig, Germany; Department of Psychiatry, Rudolf-Virchow-Klinikum Glauchau, Glauchau, Germany.

Förderung

  • Bundesministerium für Bildung und Forschung

Zitieren

APA

Galuba, V., Cordes, J., Feyerabend, S., Riesbeck, M., Meisenzahl-Lechner, E., Correll, C. U., Kluge, M., Neff, A., Zink, M., Langguth, B., Reske, D., Gründer, G., Hasan, A., Brockhaus-Dumke, A., Jäger, M., Baumgärtner, J., Leucht, S., Schmidt-Kraepelin, C., & COMBINE Study Group (2024). Identifying differential predictors for treatment response to amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill patients with schizophrenia: Results of the COMBINE-study. Schizophrenia Research. https://doi.org/10.1016/j.schres.2024.06.033

Vancouver

Galuba V, Cordes J, Feyerabend S, Riesbeck M, Meisenzahl-Lechner E, Correll CU, et al. Identifying differential predictors for treatment response to amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill patients with schizophrenia: Results of the COMBINE-study. Schizophrenia Research. 2024. doi:10.1016/j.schres.2024.06.033

BibTeX
@article{Galuba2024,
  author = {Galuba, Viktoria and Cordes, Joachim and Feyerabend, Sandra and Riesbeck, Mathias and Meisenzahl-Lechner, Eva and Correll, Christoph U and Kluge, Michael and Neff, Andrea and Zink, Mathias and Langguth, Berthold and Reske, Dirk and Gründer, Gerhard and Hasan, Alkomiet and Brockhaus-Dumke, Anke and Jäger, Markus and Baumgärtner, Jessica and Leucht, Stefan and Schmidt-Kraepelin, Christian and COMBINE Study Group, COMBINE Study Group},
  title = {Identifying differential predictors for treatment response to amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill patients with schizophrenia: Results of the COMBINE-study},
  journal = {Schizophrenia Research},
  year = {2024},
  doi = {10.1016/j.schres.2024.06.033}
}
Kostenlos starten →